Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Blood (2024) 144 (3): 334–338.

https://doi.org/10.1182/blood.2024024526

Published: 2024

Includes: Supplemental data

Journal Articles

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Jeremy S. Abramson, Aravind Ramakrishnan, Ana Alfonso Pierola, Ira Braunschweig, Guillaume Cartron, Catherine Thieblemont, Jose A. Pérez-Simón, Pere Barba, Peter A. Riedell, Carlos Solano, Thomas Gastinne, Alexandra LaCroce, Denise Thomas, Camille Poirot, Sarah Meadows, Kathryn J. Newhall, Daniel J. Lee, Mark G. Frattini, Emmanuel Bachy

Blood (2023) 142 (Supplement 1): 2110.

https://doi.org/10.1182/blood-2023-186570

Published: 2023

Journal Articles

Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

Pere Barba, Sally Lanar, Fei Fei Liu, Laurie Eliason, Kshawna Askew, Jennifer Devlen, Ulrika Furustrand, Ana Kostic

Blood (2023) 142 (Supplement 1): 7352.

https://doi.org/10.1182/blood-2023-178858

Published: 2023

Journal Articles

Retrospective and Observational Study on CAR-T 19 Bridge Therapies in Pediatric, Adolescents and Young Adults <24 Years with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Experience of the Spanish Hematopoietic Stem Cell Trasplantation and Cellular Therapy Group (GETH-TC)

Víctor Galán-Gómez, Berta González-Martínez, Anna Alonso-Saladrigues, Susana Rives, Agueda Molinos Quintana, Jose Antonio Perez Simon, Blanca Herrero-Velasco, Mi Kwon, Pere Barba, Mario Sánchez-Salinas, Lucía López-Corral, Anna Torrent, Rafael Hernani, Odelaisy Leon Triana, Antonio Pérez-Martínez

Blood (2023) 142 (Supplement 1): 6909.

https://doi.org/10.1182/blood-2023-190471

Published: 2023

Journal Articles

Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients

Blood (2023) 142 (Supplement 1): 1635.

https://doi.org/10.1182/blood-2023-186072

Published: 2023

Journal Articles

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Blood (2023) 142 (Supplement 1): 355.

https://doi.org/10.1182/blood-2023-181181

Published: 2023

Journal Articles

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

Kai Rejeski, Doris K. Hansen, Yucai Wang, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Mueller, Wolfgang Andreas Bethge, Javier L. Munoz, Razan Mohty, Veit L. Buecklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood (2023) 142 (Supplement 1): 359.

https://doi.org/10.1182/blood-2023-180607

Published: 2023

Journal Articles

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 227.

https://doi.org/10.1182/blood-2023-184942

Published: 2023

Journal Articles

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2023-186265

Published: 2023

Journal Articles

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

Blood (2023) 142 (Supplement 1): 267.

https://doi.org/10.1182/blood-2023-186388

Published: 2023

Journal Articles

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Blood (2023) 142 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2023-179061

Published: 2023

Journal Articles

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Blood (2023) 142 (Supplement 1): 6938.

https://doi.org/10.1182/blood-2023-178526

Published: 2023

Journal Articles

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Blood (2023) 142 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2023-186510

Published: 2023

Journal Articles

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Blood (2023) 142 (Supplement 1): 222.

https://doi.org/10.1182/blood-2023-179454

Published: 2023

Journal Articles

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Gloria Iacoboni, Angel Serna, Victor Navarro Garces, Ana Jimenez Ubieto, Evelyn Valencia, Alberto Lopez Garcia, Itziar Carro, Sergi Camarillas, Josu Iraola, Lucia Medina, Gala Vega, Maria Pozas, Anna Maria Sureda Balari, Raul Cordoba, Miguel Canales, Francesc Bosch, Pere Barba, Pau Abrisqueta Costa

Blood (2023) 142 (Supplement 1): 310.

https://doi.org/10.1182/blood-2023-184883

Published: 2023

Journal Articles

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 228.

https://doi.org/10.1182/blood-2023-185035

Published: 2023

Journal Articles

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Blood (2023) 142 (Supplement 1): 4883.

https://doi.org/10.1182/blood-2023-185858

Published: 2023

Journal Articles

Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Español De Trasplante y Terapia Celular (GETH-TC) Study

Blood (2023) 142 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2023-185721

Published: 2023

Journal Articles

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Blood (2023) 142 (10): 865–877.

https://doi.org/10.1182/blood.2023020578

Published: 2023

Includes: Supplemental data

Journal Articles

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Blood (2022) 140 (Supplement 1): 4549–4551.

https://doi.org/10.1182/blood-2022-167632

Published: 2022

NARROW

Efficacy of CAR T-cell therapy is not impaired by previous bispecific antibody treatment in large B-cell lymphoma

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

Retrospective and Observational Study on CAR-T 19 Bridge Therapies in Pediatric, Adolescents and Young Adults <24 Years with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Experience of the Spanish Hematopoietic Stem Cell Trasplantation and Cellular Therapy Group (GETH-TC)

Resistance Mechanisms Impacting Bispecific Antibody (BsAbs) and Chimeric Antigen Receptor (CAR) T-Cell Therapy Outcomes in Large B Cell Lymphoma (LBCL) Patients

Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival

Applying the Novel EHA/EBMT Grading System for Icaht Following CAR-T Therapy: Comparative Incidence across Disease Entities and Association with Infections and Mortality

The Post-CAR Prognostic Index (PC-PI): A New Prognostic Score to Predict Overall Survival in Large B-Cell Lymphoma Patients Progressing after Chimeric Antigen Receptor T-Cell Therapy

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Impact of Patient Selection and Management over Different Time Periods on the Outcome of Patients with Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Is CAR T a Drug or a Therapeutic Pathway? Systematic Review, (Re-)Estimation of Efficacy Endpoints and Metanalyses in Large B-Cell Lymphoma Real World Reports

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma

Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Female Sex Effect on Anti-CD19 CART Cell Therapy for Relapsed/Refractory B-Cell Lymphoma: A Grupo Español De Trasplante y Terapia Celular (GETH-TC) Study

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only